This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sequenom Study Found Unreliable

Stocks in this article: SQNM

Editor's note: Biotech expert Adam Feuerstein will be the featured guest on TSC Live at noon EDT Tuesday, Sept. 29. Email your questions at; tweet us on Twitter with hash tag #tsclive; or leave a message on our Facebook page. Bookmark the TSC Live page now.

(Updated from Monday, Sept. 28)

SAN DIEGO ( TheStreet) -- An independent investigation of the way Sequenom (SQNM) conducted a study of its genetic test for Down syndrome found that the biotech firm "failed to provide adequate protocols and controls" and that the study's data were unreliable and misreported.

The inquiry, conducted by special committe of the company's board, has led to an executive-suite purging. The company fired its chief executive, Harry Stylli, and its senior vice president of development, Elizabeth Dragon, effective immediately. Sequenom's board also "obtained the resignation" of the company's chief financial officer, Paul Hawran, as well as another as-yet-unnamed officer.

"While each of these officers and employees has denied wrongdoing," the company said in a press release, "the special committee's investigation has raised serious concerns, resulting in a loss of confidence by the independent members of the company's board of directors in the personnel involved."

The Sequenom board stopped short of asserting that any of the executives purposefully fudged the study's data.

In after-market trading, shares of Sequenom shares plunged 44.6% to $3.15, after closing at $5.69 in the regular session.

Sequenom first reported in April that data from studies of the company's test product for trisomy 21, the genetic condition that results in Down syndrome, were unreliable, citing "employee mishandling." The special committee launched its independent investigation shortly thereafter.

The results of that probe, released after Monday's market close, appeared to corroborate the worst.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs